EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment response after chemoradiation with an external beam radiation therapy boost in cervical cancer patients in Rwanda

Dieudonne Duhoranenayo iD, Sabine Esperance Nyiraneza iD, Eulade Rugengamanzi iD, Richard Sungura, Emmanuel Rudakemwa iD, Cherise Umutoni Gahizi, Joseph Musabyimana iD, Theoneste Maniragaba iD, Pacifique Nikuze iD, Jean Jacques Nshizirungu iD, Jean Paul Ruboneka, Rafi Kabarriti und 1 weitere

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf328 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Dieudonne Duhoranenayo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Imaging Department, University Teaching Hospital of Kigali (CHUK) (Centre Hospitalier Universitaire de Kigali), Kigali 655, Rwanda. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Chemoradiotherapy. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cervical cancer remains a significant public health burden in Rwanda, where brachytherapy is not widely available. This study assessed treatment response in cervical cancer patients post-chemoradiation using magnetic resonance imaging (MRI)-based Response Evaluation Criteria in Solid Tumors (RECIST), focusing on the effectiveness of external beam boost as an alternative. Patients and Methods This retrospective study was conducted at the Rwanda Cancer Centre, including patients treated with chemoradiation followed by an external beam boost from January 2020 to June 2022. MRI scans performed before treatment and 3-6 months post-treatment were analyzed using RECIST criteria to classify treatment response as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). Agreement between clinical and MRI staging pre- and post-treatment was assessed using kappa coefficients.

Results

Eighty-eight patients were included (mean age: 57.7 ± 10.6 years). CR, PR, SD, and PD were observed in 67%, 17%, 9%, and 7% of patients, respectively. MRI findings demonstrated substantial agreement with clinical staging before pre-treatment (78%, K = 0.63) and after post-treatment (71%, K = 0.71). CR rates were highest in early-stage disease (FIGO stage I: 90%), whereas PD was more frequent in advanced stages (FIGO stage II: 9%; FIGO stage III: 13%).

Conclusion

The MRI-based RECIST criteria effectively assess the cervical cancer treatment response after post-chemoradiation. The high CR rate (67%) suggests that an external beam boost may serve as a viable alternative for brachytherapy. However, PD in advanced-stage disease highlights the need for further research to optimize treatment strategies. Future studies should evaluate long-term outcomes and explore advanced MRI techniques to enhance the response assessment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsChemoradiotherapyHumansFemaleMiddle AgedRwandaRetrospective StudiesMagnetic Resonance ImagingBrachytherapyAgedAdultTreatment OutcomeResponse Evaluation Criteria in Solid Tumors

Stichwörter der Autor:innen

MRIcervical cancerchemoradiation therapytreatment response and RECIST criteria

Autor:innen und Institutionen

  • Imaging Department, University Teaching Hospital of Kigali (CHUK) (Centre Hospitalier Universitaire de Kigali), Kigali 655, Rwanda.
  • Diagnostic Imaging and Radiation Sciences Department, College of Medicine and Health Sciences, University of Rwanda, Kigali 4285, Rwanda.
  • Oncology Department, Butaro Hospital, Burera, Musanze 59, Rwanda.
  • Medical Imaging Department, Rwanda Military Hospital (RMH), Kigali 3377, Rwanda.
  • Imaging and Diagnostic Department, King Faisal Hospital, Kigali 2534, Rwanda.
  • Oncology Department, Rwanda Military Hospital (RMH), Kigali 3377, Rwanda.

ORCID-Profile: Dieudonne Duhoranenayo, Sabine Esperance Nyiraneza, Eulade Rugengamanzi, Emmanuel Rudakemwa, Joseph Musabyimana, Theoneste Maniragaba, Pacifique Nikuze, Jean Jacques Nshizirungu, Fidel Rubagumya

Zitieren

APA

Duhoranenayo, D., Nyiraneza, S. E., Rugengamanzi, E., Sungura, R., Rudakemwa, E., Gahizi, C. U., Musabyimana, J., Maniragaba, T., Nikuze, P., Nshizirungu, J. J., Ruboneka, J. P., Kabarriti, R., & Rubagumya, F. (2025). Treatment response after chemoradiation with an external beam radiation therapy boost in cervical cancer patients in Rwanda. The Oncologist. https://doi.org/10.1093/oncolo/oyaf328

Vancouver

Duhoranenayo D, Nyiraneza SE, Rugengamanzi E, Sungura R, Rudakemwa E, Gahizi CU, et al. Treatment response after chemoradiation with an external beam radiation therapy boost in cervical cancer patients in Rwanda. The Oncologist. 2025. doi:10.1093/oncolo/oyaf328

BibTeX
@article{Duhoranenayo2025,
  author = {Duhoranenayo, Dieudonne and Nyiraneza, Sabine Esperance and Rugengamanzi, Eulade and Sungura, Richard and Rudakemwa, Emmanuel and Gahizi, Cherise Umutoni and Musabyimana, Joseph and Maniragaba, Theoneste and Nikuze, Pacifique and Nshizirungu, Jean Jacques and Ruboneka, Jean Paul and Kabarriti, Rafi and Rubagumya, Fidel},
  title = {Treatment response after chemoradiation with an external beam radiation therapy boost in cervical cancer patients in Rwanda},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf328}
}
Kostenlos starten →